Jefferies analyst Dennis Ding downgraded Corcept Therapeutics to Hold from Buy with a price target of $22, down from $35.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on CORT:
- Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2022 Financial Results, Provide Corporate Update and Host Conference Call
- Corcept Therapeutics Announces Preliminary Settlement of Purported Securities Class Action Litigation
- Corcept Therapeutics to pay $14M in settlement of class action litigation